Sirolimus News and Research

RSS

Drug-coated balloons reduce the need for permanent heart stents

A new sub-study suggests that using a sirolimus-eluting balloon (SEB), a drug-coated balloon, can reduce the number of stents a patient may need, making it a safe and effective way to treat certain heart attacks or unstable chest pain.

23 Apr 2026

Milken Institute and Ann Theodore Foundation fund mTOR inhibitor trial for sarcoidosis

The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), in partnership with the Ann Theodore Foundation (ATF), has launched a new funding program to support a future clinical trial in cutaneous sarcoidosis.

20 Feb 2026

Sirolimus-eluting balloon emerges as a safe and effective option for coronary in-stent restenosis

A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis (ISR) undergoing repeated percutaneous coronary intervention (PCI).

31 Oct 2025

Landmark trial shows drug-eluting balloon as effective option for in-stent restenosis

Results from the first randomized clinical trial in the United States to compare a sirolimus-eluting balloon (DEB) to control group consisting of drug-eluting stent (DES) and balloon angioplasty (BA) for the treatment of bare-metal and DES in-stent restenosis (ISR) deemed DEB to be noninferior to conventional therapies.

28 Oct 2025

Sirolimus-eluting balloon strategy matches drug-eluting stents in large international PCI trial

New study results from a large international all-comer population of percutaneous coronary intervention (PCI) candidates found that utilizing a strategy of sirolimus-eluting balloons with bailout stenting only if necessary was noninferior to routine drug-eluting stent (DES) implantation as part of the treatment for de novo coronary artery disease.

27 Oct 2025

Key triggers for food allergies in children after organ transplants

Study reviews transplant-acquired food allergies, focusing on pediatric patients, particularly liver transplant recipients. It explores immune system dysfunction, immunosuppressive agents, and gut microbiota changes as contributors to the rise of food allergies after organ transplants.

23 Sep 2024

TCT 2024 to feature latest advances in interventional cardiovascular medicine

The Cardiovascular Research Foundation is pleased to announce the late-breaking clinical trials and science to be featured at TCT 2024.

28 Aug 2024

Novel drug combination shows promise for treating advanced skin cancers in kidney transplant recipients

People who have had a kidney transplant are at high risk for developing skin cancers. New research directed by investigators from the Johns Hopkins Kimmel Cancer Center is exploring the best combination of treatments to target skin cancers while preserving the transplanted organs.

28 Feb 2024

Scientists identify a new approach to treating sarcoidosis

A research team led by Georg Stary (Medical University of Vienna and CeMM) has identified a new approach to treating the inflammatory disease sarcoidosis.

23 Jan 2024

3D nanomatrix vascular sheet model for high-throughput atherosclerosis drug testing

A groundbreaking 3D, three-layer nanomatrix vascular sheet that possesses multiple features of atherosclerosis has been applied for developing a high-throughput functional assay of drug candidates to treat this disease, University of Alabama at Birmingham researchers report in the journal Biomaterials.

12 Jan 2024

Discovery of two new enzymes offers easier ways to study and manufacture complex natural chemicals

Slumbering among thousands of bacterial strains in a collection of natural specimens at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, several fragile vials held something unexpected, and possibly very useful.

13 Nov 2023

Rice engineers develop split gene-editing tool with enhanced control

To make a gene-editing tool more precise and easier to control, Rice University engineers split it into two pieces that only come back together when a third small molecule is added.

21 Sep 2023

UC researchers discover treatment for a rare cancer-like lung disease in women

A treatment for a rare cancer-like lung disease found in women of childbearing age may have been discovered by University of Cincinnati researchers.

15 Jun 2023

Rapamycin and other rapalogs have potential to delay cancer

A new research perspective was published in Oncotarget's Volume 14 on April 14, 2023, entitled, "Cancer prevention with rapamycin."

18 Apr 2023

Does nirmatrelvir and ritonavir reduce the risk of hospitalization or death among outpatients with early COVID-19?

Researchers investigated the efficacy of ritonavir and nirmatrelvir combination treatment in reducing the risk of COVID-19 severity outcomes such as hospital admissions and deaths when administered during the initial period of SARS-CoV-2 infections.

16 Dec 2022

Results from Phase 0/1 trial of ribociclib plus everolimus in patients with high-grade glioma announced

The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer in the world, announced results from their Phase 0/1 clinical trial of ribociclib plus everolimus in patients with high-grade glioma (HGG).

13 Sep 2021

Research uncovers test to identify iMCD patients with superior response to FDA-approved treatment

New research has uncovered a precision medicine test using blood proteins to identify a novel patient subgroup of idiopathic multicentric Castleman disease (iMCD), a rare blood disorder, who are more likely to respond to siltuximab, the only FDA approved treatment for the disease.

2 Sep 2021

Study explores therapeutic potential of exploiting autophagy cascade against COVID-19

Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.

7 Jun 2021

UC study tests efficacy of immune regulating drug in treating patients with COVID-19 pneumonia

Researchers at the University of Cincinnati are testing a commonly used drug, called sirolimus, to determine its safety and efficacy in treating hospitalized patients with COVID-19 pneumonia in the trial.

15 Jul 2020

Scientist proposes geroprotective strategies to reduce lethality of COVID-19 in the elderly

The Biogerontology Research Foundation, a registered UK charity supporting and promoting aging and longevity research worldwide since 2008, today announced the publication of a paper titled "Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections" in the leading journal Aging.

6 Apr 2020